Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Collaboration agreements	$ 5,678	$ 408
Operating expenses:
Research and development, net of tax credits	31,830	26,458
General and administrative	8,529	8,779
Total operating expenses	40,359	35,237
Loss from operations	(34,681)	(34,829)
Other income (expense), net
Realized and unrealized loss on foreign exchange	(56)	(17)
Interest income	3,427	129
Other expense	(15)	(8)
Total other income, net	3,356	104
Loss before income taxes	(31,325)	(34,725)
Income tax expense	(3,616)	(32)
Net loss	(34,941)	(34,757)
Unrealized gain on available-for-sale marketable securities	193	0
Total other comprehensive gain	193	0
Comprehensive loss	$ (34,748)	$ (34,757)
Net loss per share attributable to common shareholders--basic	$ (0.83)	$ (0.83)
Net loss per share attributable to common shareholders--diluted	$ (0.83)	$ (0.83)
Weighted-average common shares outstanding-basic	42,040,674	41,861,613
Weighted-average common shares outstanding-diluted	42,040,674	41,861,613